financetom
Business
financetom
/
Business
/
--CVS Health Keeps Quarterly Dividend at $0.665 a Share, Payable May 1 to Shareholders of Record April 22
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--CVS Health Keeps Quarterly Dividend at $0.665 a Share, Payable May 1 to Shareholders of Record April 22
Mar 21, 2024 11:14 AM

01:48 PM EDT, 03/21/2024 (MT Newswires) --

Price: 78.29, Change: -0.69, Percent Change: -0.87

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SiriusXM's second-quarter subscription loss narrows on strong content demand
SiriusXM's second-quarter subscription loss narrows on strong content demand
Aug 1, 2024
Aug 1(Reuters) - SiriusXM posted a lower-than-expected drop in subscribers who directly pay for its satellite radio service, helped by steady demand for its content that includes the Howard Stern show. Decline in the key subscription segment narrowed sequentially and from a year ago largely due to strong customer retention, the company said. We still expect to see slightly better...
Belden Shares Rise After Q2 Beat
Belden Shares Rise After Q2 Beat
Aug 1, 2024
10:23 AM EDT, 08/01/2024 (MT Newswires) -- Belden (BDC) shares rose 9.3% in recent Thursday trading after the company reported Q2 results that surpassed analysts' estimates. The company reported Q2 adjusted earnings of $1.51 per diluted share, down from $1.91 a year earlier. Analysts polled by Capital IQ expected $1.37. Revenue for the quarter ended June 30 was $604.3 million,...
Eli Lilly Says Tirzepatide Cuts Heart-Failure Risks in Study
Eli Lilly Says Tirzepatide Cuts Heart-Failure Risks in Study
Aug 1, 2024
10:09 AM EDT, 08/01/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday its phase 3 clinical trial showed that Tirzepatide demonstrated statistically significant improvements in the reduction of heart-failure risks as well as improvements in heart-failure symptoms and physical limitations compared with a placebo. Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist that...
Standard Lithium names David Park as CEO
Standard Lithium names David Park as CEO
Aug 1, 2024
Aug 1 (Reuters) - Canadian miner Standard Lithium ( SLI ) on Thursday named David Park as its new chief executive officer, effective Sept. 1, succeeding longtime CEO Robert Mintak. The incoming CEO has served as a strategic advisor for Standard Lithium ( SLI ) over the past year and helped the lithium miner secure an investment from Equinor ASA...
Copyright 2023-2026 - www.financetom.com All Rights Reserved